National Bank of Canada’s SQZ Biotechnologies Company SQZ Stock Holding History

National Bank of Canada’s Portfolio SQZ Stock Details SQZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$558	–	2863
2023 Q1	$558	Hold	1,000	–	–	﹤0.01%	2583
2022 Q4	$710	Hold	1,000	–	–	﹤0.01%	2620
2022 Q3	$2K	Hold	1,000	–	–	﹤0.01%	2561
2022 Q2	$3K	Buy	+1,000	New	+$3.6K	﹤0.01%	2573

Other funds holding SQZ

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

National Bank of Canada's SQZ Position: Q2 2023 in Review

National Bank of Canada sold out of SQZ Biotechnologies Company (SQZ) in Q2 2023, closing a stake of 1,000 shares — an estimated $558 sold.

National Bank of Canada first reported a position in SQZ in Q2 2022 and held it in 4 quarters. The position peaked at $3K in Q2 2022. 31 funds tracked by Wall St. Rank hold SQZ as of Q2 2023.

National Bank of Canada reported no remaining SQZ Biotechnologies Company position as of Q2 2023 after selling out during the quarter.
National Bank of Canada sold 1,000 SQZ Biotechnologies Company shares in Q2 2023, an estimated $558.
National Bank of Canada first reported a position in SQZ Biotechnologies Company in Q2 2022 and held it in 4 quarters.
National Bank of Canada's SQZ Biotechnologies Company position peaked at $3K in Q2 2022.
31 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q2 2023.

Based on National Bank of Canada's 13F filing for Q2 2023, filed 26 Jul 2023.